Despite Delivering Investors Losses of 65% Over the Past 3 Years, STAAR Surgical (NASDAQ:STAA) Has Been Growing Its Earnings
It is doubtless a positive to see that the STAAR Surgical Company (NASDAQ:STAA) share price has gained some 61% in the last three months. But that is small recompense for the exasperating returns o
Apple To $210? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan
Staar Surgical Is Maintained at Buy by Mizuho
Staar Surgical Is Maintained at Buy by Mizuho
Mizuho Bank: Maintaining the Staar Surgical (STAA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $45.00 to $53.00.
Mizuho Bank: Maintaining the Staar Surgical (STAA.US) rating, adjusted from buy to buy rating, and adjusted the target price from $45.00 to $53.00.
Mizuho Maintains Buy on Staar Surgical, Raises Price Target to $53
Mizuho analyst Anthony Petrone maintains Staar Surgical (NASDAQ:STAA) with a Buy and raises the price target from $45 to $53.
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Ocugen (OCGN) and Moderna (MRNA)
Staar Surgical Is Maintained at Hold by Canaccord Genuity
Staar Surgical Is Maintained at Hold by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the Staar Surgical (STAA.US) rating, adjusted from holding to holding rating, and adjusted the target price from $32.00 to $46.00.
Canadian Investment Banking Group: Maintaining the Staar Surgical (STAA.US) rating, adjusted from holding to holding rating, and adjusted the target price from $32.00 to $46.00.
Canaccord Genuity Maintains Hold on Staar Surgical, Raises Price Target to $46
Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:STAA) with a Hold and raises the price target from $32 to $46.
STAAR Surgical Shares Are Trading Higher After the Company Recently Issued Strong Preliminary Q1 Net Sales Guidance.
STAAR Surgical Shares Are Trading Higher After the Company Recently Issued Strong Preliminary Q1 Net Sales Guidance.
Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn Into More Strength?
Staar Surgical Holds Promise Amid Strong Q1 Performance, Yet Cautious Outlook Justifies Hold Rating
Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus
Thursday, STAAR Surgical Company (NASDAQ:STAA) reported preliminary net sales for the first quarter of 2024 of more than $77 million versus the consensus of $72.13 million, with U.S. ICL sales expecte
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday's session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%
Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)
Update: STAAR Surgical Shares Jump After Reporting Preliminary Fiscal Q1 Sales
(Updates with latest stock move in the headline and first paragraph.) STAAR Surgical (STAA) shares jumped more than 17% in recent Thursday trading after the company said it expects preliminary fiscal
In-Depth Examination Of 4 Analyst Recommendations For Staar Surgical
Throughout the last three months, 4 analysts have evaluated Staar Surgical (NASDAQ:STAA), offering a diverse set of opinions from bullish to bearish.The table below provides a snapshot of their recent
STAAR Surgical Up Over 15%, On Track for Largest Percent Increase Since August 2022 -- Data Talk
STAAR Surgical Company (STAA) is currently at $45.00, up $5.93 or 15.18% --Would be highest close since Aug. 9, 2023, when it closed at $45.43 --On pace for largest percent increase since Aug. 11, 2
Needham Reiterates Hold on Staar Surgical
Needham analyst David Saxon reiterates Staar Surgical (NASDAQ:STAA) with a Hold.
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA) and Schrodinger (SDGR)
No Data